CD11a (LFA-1alpha) Monoclonal Antibody (HI111), FITC, eBioscience™, Invitrogen™

Description

• Description: The HI111 monoclonal antibody reacts with human CD11a, the 180 kDa integrin alphaL, also known as the lymphocyte function associated antigen-1 (LFA-1) alpha chain
• LFA-1, formed by non-covalent association of CD11a with CD18 (integrin beta2), serves as an important adhesion molecule involved in lymphocyte and granulocyte function
• CD54 (ICAM-1), CD102 (ICAM-2), and CD50 (ICAM-3) are ligands for LFA-1
• CD11a is expressed by all leukocytes
• Applications Reported: The HI111 antibody has been reported for use in flow cytometric analysis
• Applications Tested: The HI111 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (1 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser
• Filtration: 0.2 μm post-manufacturing filtered
• CD11a (LFA-1 alpha, ITGAL) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the alphaLbeta2 integrin
• CD11a is implicated in activation of LFA-1 complex
• CD11a plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAMs 1-3 (intercellular adhesion molecules 1 through 3), and also functions in lymphocyte costimulatory signaling
• CD11a is expressed on the plasma membrane of leukocytes in a low-affinity conformation
• Cell stimulation by chemokines or other signals leads to induction the high-affinity conformation, which supports tight binding of CD11a to its ligands, the intercellular adhesion molecules ICAM-1, -2, -3
• CD11a is thus involved in interaction of various immune cells and in their tissue-specific settlement, but participates also in control of cell differentiation and proliferation and of T-cell effector functions
• Blocking of CD11a function by specific antibodies or small molecules has become an important therapeutic approach in treatment of multiple inflammatory diseases
• For example, humanized anti- CD11a antibody Efalizumab (Raptiva) is being used to interfere with T cell migration to sites of inflammation, binding of cholesterol-lowering drug simvastatin to CD11a allosteric site leads to immunomodulation and increase in lymphocytic cholinergic activity
• Two transcript variants encoding different isoforms of CD11a have been found
• Diseases associated with CD11a dysfunction include benign cephalic histiocytosis and leukocyte adhesion deficiency.